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Abstract
Upper respiratory tract infections (URTIs) in the elderly (those aged 65 years and older) are not more common than in 
younger people, but complications are more common. Influenza and respiratory syncitial virus are the two most common 
pathogens affecting morbidity and mortality. Hospitalisation, bronchitis, pneumonia and death are all significantly increased 
in the elderly. Influenza vaccine is recommended for all persons aged 65 and older. Antibiotics have no benefit in the 
treatment or prevention of complications from influenza. Otitis media and tonsillitis are uncommon. Sinusitis should be 
treated with antibiotics. Amoxycillin remains the drug of choice for patients who are not allergic to penicillin. Pneumococcal 
vaccine is recommended as prophylaxis against pneumococcal pneumonia, which is often seen as a complication of 
influenza. Chronic idiopathic cough, anosmia, gastroesophageal reflux disease, asthma and chronic post-nasal drip may all 
present as upper respiratory tract-like illness. There is no benefit from using common cough mixtures or many other OTC 
preparations for the management of URTIs, as their side effects are significantly greater in older persons. 
SA Fam Pract 2006;48(5): 20-23)
Introduction
Upper respiratory tract infections 
(URTIs) in older persons are seen 
commonly in general practice. Older 
persons who suffer from an URTI 
may have decreased daily activity 
and slower recovery from their illness, 
may access healthcare services more 
frequently and may have more severe 
complications, including death, than 
their younger cohorts.1 
Factors that play a role in the 
severity of disease include immunosen-
escence, i.e. impaired immune and 
inflammatory changes that occur with 
old age.2 Older individuals may not 
respond well to therapy for infections 
and may also not present with 
“typical signs” of infection, e.g. fever. 
Anatomical changes that occur in the 
upper airways, e.g. reduced ciliary 
escalator efficiency, cough reflex in-
crease and gastroesophageal reflux 
disease, may predispose an older 
person to an increased risk of URTI. 
Living in close confines, e.g. in a long-
term care facility, has been implicated 
in an increased risk of URTI in older 
residents. Such populations must be 
viewed as a specific group of people 
at high risk of URTI, especially during 
winter flu epidemics.   
Influenza and Respiratory Syncitial 
Virus (RSV) are the two most common 
viral URTIs that occur in the elderly. 
Pneumococcal disease is up to 14 
times more common in people aged 
70 years and over than in younger 
individuals. The pneumococcus is a 
common pathogen in the nasopharynx 
and is most commonly associated 
with pneumonia. However, it is also 
commonly implicated in otitis media 
and sinusitis. 
Influenza
Influenza is characterised by a sudden 
onset of fever, muscle aches and 
pains, malaise, and upper respiratory 
tract symptoms, including rhinitis, sore 
throat and non-productive cough. The 
incubation period typically is one to two 
days. Some influenza infections are 
associated with minor symptoms and 
virological studies have shown that at 
least 10% of URTIs in elderly people 
are due to influenza.3 Older persons 
may not present with the above typical 
symptoms, and during the influenza 
season one should suspect influenza 
if patients present with lassitude, fever 
and confusion.4 
Influenza is not more common 
in older persons than in the general 
population, although sequelae of 
influenza are greater. Hospitalisation is 
up to 20 times more likely in older per-
sons, and especially among those who 
have concomitant chronic diseases 
such as cardiac, pulmonary or renal 
disease. Approximately 25% of elderly 
patients will suffer complications due 
to influenza. Bronchitis is up to 20 
times more common and pneumonia 
up to 10 times more likely to occur. 
Figure 1 shows the estimated annual 
mortality associated with influenza and 
respiratory syncitial virus in the USA 
for the period 1990–1999.5 
Figure 1: Estimated annual mortality 
rates associated with influenza and 
Respiratory Syncitial Virus (rates per 
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Secondary bacterial pneumonia 
is the most common and most se-
rious complication post influenza. 
Bacterial pneumonia is most likely 
due to Streptococcus pneumoniae. 
However, Staphylococcal pneumonia 
accounts for up to a quarter of all 
post-influenza bacterial pneumonias. 
With a bacterial pneumonia, there is 
often an initial improvement in the 
influenza symptoms, followed five 
to 10 days later with a relapse of the 
symptoms, i.e. high fever, productive 
cough and mucopurulent sputum. A 
chest X-ray usually shows signs of 
consolidation.
Unlike bacterial pneumonia, viral 
pneumonia due to influenza occurs 
three to five days after the onset of the 
initial influenza symptoms. Patients 
typically present with worsening 
cough, tachypnea, dyspnea and 
fever. Chest X-rays usually show 
bilateral patchy infiltrates, although 
localised infiltrates may occasionally 
be seen. The disease can progress 
rapidly over one to four days, resul-
ting in severe respiratory failure and 
death.
The general practitioner is ideally 
situated to diagnose influenza in 
older people, as these practitioners 
are actively involved in the health 
of their communities and know 
when the influenza season begins. 
The use of viral cultures is the gold 
standard for diagnosing influenza 
and typing the strain present in 
the community. However, the tests 
are costly and need to be taken 
within three days of the onset of 
symptoms, and the results are often 
not available rapidly enough to 
initiate antiviral therapy.4
Prevention of influenza through 
the use of an inactivated influe-nza 
virus vaccine annually is recom-
mended. An influenza vaccine is 
recommended for all persons aged 
65 years and older and all residents of 
long-term care facilities. Vaccination 
is also recommended for persons 
who can transmit influenza to elderly 
patients, such as healthcare workers, 
community workers who provide 
services to the elderly and persons in 
frequent contact with older persons, 
e.g. family members. 
The influenza vaccine is not 
universally effective in producing 
an antibody response and only 40 
to 60 % of older persons develop an 
effective immune response within 10 
to 14 days of receiving the vaccine. 
However, the primary goal of the 
influenza vaccine is not to prevent 
influenza epidemics, but rather to 
reduce the serious sequelae of 
the disease. Prevaccination titres 
of antibodies to influenza and 
the number of previous influenza 
vaccinations have been shown to in-
fluence post-vaccination titres. 
Vaccination against influenza 
has been shown to significantly 
reduce the risk of hospitalisation 
for heart disease, cerebrovascular 
disease and pneumonia, which all 
cause mortality during an influenza 
season. The risks associated with 
the influenza vaccine are negligible 
and its use is only contraindicated in 
people with an egg allergy. Regular, 
repeated vaccinations are more 
effective and persons who have 
had annual vaccinations for the prior 
four years are more likely to develop 
immunity. Studies have shown that 
the most common reason why most 
people do not receive vaccination is 
a lack of information from their GP, 
a fear of side effects and concern 
about vaccine efficacy. It is thus 
incumbent upon a GP to offer an 
influenza vaccine to all eligible 
elderly patients.
Antiviral drugs, such as aman-
tadine and zanamavir, are available 
for the treatment of influenza. These 
drugs need to be used within 48 
hours of the start of symptoms. 
Amantadine has been shown to 
be effective in nursing homes as 
prophylaxis during an influenza 
outbreak. The drugs are not a 
substitute for the influenza vaccine 
and should be used as an adjunct 
to the vaccine. Amantadine is 
only effective against influenza 
and has been shown to reduce 
disease severity. However, due 
to neurological side effects and 
the rapid emergence of resistant 
strains, its use has been limited. The 
recommended dose of amantadine 
is 100 mg daily. It is excreted via the 
kidneys and thus should be used 
with caution in patients with renal 
impairment. When an outbreak of 
influenza occurs in a nursing home, 
amantadine should be used for a 
minimum of two weeks.    
Zanamavir is a neuraminidase 
inhibitor that has been shown to 
reduce the symptoms of influenza 
by 0.9 days and evidence for its 
effectiveness in treating high-risk 
groups is limited.6
Respiratory Syncitial Virus
Respiratory Syncitial Virus (RSV), 
together with rhinovirus and 
influenza virus, is among the three 
most common viral pathogens 
identified in hospitalised patients 
in the winter.4,7 It is a paromyxovirus 
and an important cause of lower 
respiratory tract infections in elderly 
patients, particularly those living 
in long-term care facilities and in 
households with children.
Clinical symptoms are not unlike 
influenza, but may range from those 
of a mild cold to severe respiratory 
distress. Fever occurs in only 50% 
of patients, and the patients are 
more commonly found to have signs 
of lower respiratory tract infection, 
i.e. wheezes and crackles. RSV 
infection may be diagnosed using 
laboratory techniques such as viral 
cultures from the nasopharynx, 
RSV-specific IgM, or a four-fold 
increase in IgG titres between acute 
and convalescent phase serum 
samples. In elderly patients there 
is a reduced sensitivity to these 
tests, and due to their cost they are 
not recommended routinely. Rapid 
tests are being developed and may 
become more accessible within 
general practice in the near future.
The treatment of RSV in the 
elderly is mainly supportive, i.e. 
adequate hydration, oxygen and 
bronchodilators. Aerosolised ribavirin 
is approved in the USA, but is not 
available in South Africa. Evidence 
as to its efficacy in older persons is 
lacking and in the USA it is seldom 
used. 
      
Sinusitis, otitis media and tonsillitis
There is a lack of evidence on the 
management of sinusitis, otitis media 
and sinusitis in elderly people. The 
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recommendations of clinical guide-
lines for all adults.  
Streptococcal pharyngotonsillitis 
is uncommon in adults older than 
45. The presence of a temperature 
>38 °C, tonsillar exudates, anterior 
cervical and an acute onset of 
sore throat point towards bacterial 
pharyngotonsillitis. The presence 
of rhinorhea, cough, diarrhoea and 
conjunctivitis mitigate against a 
bacterial aetiology. South African 
guidelines for management recom-
mend the use of penicillin VK 500 
mg bid for 10 days, or benzathine 
penicillin 1.2 mu IM. For penicillin-
allergic individuals, an erythromycin-
based antibiotic is recommended.
Otitis media is relatively uncom-
mon in older persons, although if 
a bacterial infection is suspected, 
the most likely organism is a 
streptococcus. Current guidelines 
suggest the use of amoxicillin 500-
1000 mg three times a day for five 
days. In penicillin-allergic persons, 
the recommended alternative re-
mains an erythromycin-based anti-
biotic for five to seven days, except 
in the case of clarithromycin, which 
can be used for three days.
Sinusitis should be suspected 
in individuals who have an upper 
respiratory tract infection that is 
not improving after 10 days or 
worsens after five to seven days. 
It is accompanied by some of the 
following symptoms: fever, facial 
tenderness over the sinuses, dental 
tenderness, nasal discharge, anos-
mia and nasal congestion. The 
most likely bacterial pathogen is 
the streptococcus. Amoxycillin 500-
1000 mg three times a day for 10 
days is recommended. In penicillin-
allergic individuals, a macrolide 
or quinolone-based antibiotic is 
recommended for 10 days. Should a 
patient not respond within 72 hours, 
have periorbital swelling, have any 
signs of CNS involvement, e.g. 
meningism and/or an altered level of 
consciousness or focal neurological 
signs or severe systemic illness, 
the patient should be referred to a 
specialist for further management. 
Polyvalent pneumococcal vac-
cine (Pneumovax) causes a B-cell 
response. The response is ad-
vantageous in older people, as 
immunosenescence affects mostly 
T-cell immunity. It is thus advisable 
to vaccinate all people over the age 
of 65 with a pneumococcal vaccine. 
The vaccine may be re-administered 
every five years. Some studies 
have shown a prevention rate of 
pneumonia of as high as 60-95% in 
immunocompetent older and high-
risk patients.9
Pitfalls in management
Most upper respiratory tract infec-
tions are self-limiting and the wise 
GP knows that, in many instances, 
watchful waiting together with the 
body’s own defence system will 
deal with the majority of problems. 
Recently, a number of conditions 
that may mimic URTIs have been de-
scribed. The concern with not having 
a correct diagnosis is that people 
will make use of over-the-counter 
preparations for the treatment of 
their conditions, thereby leading to 
unnecessary expense and, most 
importantly, unwarranted side ef-
fects from the myriad of less than 
efficacious drugs available from 
pharmacies and supermarkets.
Olfactory impairment exists in 
about 4.6% of people over the age 
of 75 and the prevalence increases 
with age. It is important to be able 
to distinguish that a loss of smell 
in older persons is a physiological 
change associated with ageing and 
is not due to an infection.10
Chronic cough is defined as 
lasting longer than eight weeks. The 
most common causes of chronic 
cough are asthma, gastroesophageal 
reflux disease and post-nasal drip. 
No cause is found in a small group 
of patients, even after extensive 
investigation. These patients are 
labelled as having chronic idiopathic 
cough (CIC). Classically, patients 
will have had an initial minor URTI 
that triggers the cough, yet, despite 
the infection subsiding, the cough 
persists for months or years. These 
patients have often tried a number 
of empiric therapies, all of which are 
ineffective. The patients tend to have 
very sensitive cough reflexes and 
cough is triggered by eating crumbly 
foods, such as bread and biscuits, 
and exposure to strong smells from 
perfume. The mechanism of CIC is 
unknown, but it is thought to be due 
to hyperalgesia with a reduction in 
sensory nerve stimulation to pain.11
Conclusion
Upper respiratory tract infections 
are mostly self-limiting, although 
complications resulting from influ-
enza and other viral aetiologies can 
have dire consequences in older 
persons. The general practitioner 
has been shown to be an effective 
agent for getting patients to accept 
the influenza vaccine. GPs must be 
prudent in advising treatments with 
little or no efficacy, such as antibiotics 
and over-the-counter cough and 
“cold” remedies, in the hope that 
these will lessen the patient’s illness. 
Most evidence suggests that most 
URTIs will get better and the harm 
done by unproven therapies can 
be far greater than the good done. 
The GP is the person who is placed 
best to educate and inform patients 
about the best practice in managing 
URTIs.  
See CPD Questionnaire, page 50
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